Tier 4 — mechanistic

Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)

Mayo Clinic study team
ClinicalTrials.gov trial registry record 2022

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Mayo Clinic.
Competing interests
Not reported in the registry record.

Study snapshot

DesignPhase 2 placebo-controlled interventional trial.
ModelAdults with common variable immunodeficiency and granulomatous-lymphocytic interstitial lung disease.
SamplePlanned enrollment: 20 participants.
InterventionFisetin approximately 20 mg/kg/day on Days 0, 1, 28 and 29 versus placebo.
DurationApproximately one month of intermittent dosing with clinical/radiologic follow-up to 6 months.
EndpointsQuantitative radiologic interstitial-lung-disease measures; Pulmonary outcomes; Safety and tolerability; Exploratory senescence/inflammation measures

What the study showed, in plain terms

This Mayo Clinic Phase 2 trial tests intermittent fisetin against placebo in people with CVID-associated interstitial lung disease. The main question is whether the treatment changes lung disease measured quantitatively on imaging.

The parent registry remains active but not recruiting, with no final results posted. A separate May 2026 published meeting abstract reports exploratory findings from 10 participants; this is not the completed 20-person trial's final peer-reviewed report.

Key findings

  • Planned enrollment is 20 participants.
  • Fisetin is given on four treatment days: Days 0, 1, 28 and 29.
  • The primary disease context is CVID-associated interstitial lung disease, not general respiratory health.
  • May 2026 conference abstract of 10 participants reports exploratory lung-function and tolerability observations; the planned 20-person parent registry has no final results posted.

What this study can and cannot tell us

  • No final registry results or full results paper; a separate May 2026 meeting abstract reports n=10 preliminary observations.
  • Very small disease-specific sample.
  • Findings may not generalize to other interstitial lung diseases or healthy supplement use.

Related papers in the corpus

Tier 2
Novel Senolytic Clinical Trial in CVID with GLILD
Mitchell Dittus et al. · Journal of Human Immunity · 2026

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology